74 related articles for article (PubMed ID: 19344007)
1. Revolutionary changes in salvage treatment for Hodgkin lymphoma: toward a chemotherapy-free future.
Chen J; Yang W; Gong Z
Ann Transl Med; 2018 Jun; 6(11):237. PubMed ID: 30023400
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of modified rituximab-ESHAP therapy for relapsed/refractory B-cell lymphoma.
Ueda K; Nannya Y; Asai T; Yamamoto G; Hangaishi A; Takahashi T; Imai T; Kurokawa M
J Chemother; 2010 Feb; 22(1):54-7. PubMed ID: 20227994
[TBL] [Abstract][Full Text] [Related]
3. Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.
Goel A; Spitz DR; Weiner GJ
J Cell Biochem; 2012 Feb; 113(2):419-25. PubMed ID: 21956712
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes.
Smith LK; Cidlowski JA
Prog Brain Res; 2010; 182():1-30. PubMed ID: 20541659
[TBL] [Abstract][Full Text] [Related]
5. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
7. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
9. Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphoma.
Lazar AD; Shpilberg O; Shaklai M; Bairey O
Isr Med Assoc J; 2009 Jan; 11(1):16-22. PubMed ID: 19344007
[TBL] [Abstract][Full Text] [Related]
10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide in the treatment of lymphoma.
Coiffier B
Semin Oncol; 1996 Jun; 23(3 Suppl 7):2-7. PubMed ID: 8711498
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
